Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Respiratory syncytial virus vaccine - Advaccine Biopharmaceuticals

Next Previous
Drug Profile

Respiratory syncytial virus vaccine - Advaccine Biopharmaceuticals

Alternative Names: ADV-110; BARS-13; Recombinant respiratory syncytial virus vaccine - Advance Vaccine Laboratories; rRSV - Advance Vaccine Laboratories

Latest Information Update: 09 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advance Vaccine Laboratories
  • Developer Advaccine (Suzhou) Biopharmaceuticals
  • Class Respiratory syncytial virus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 02 Apr 2024 Advaccine Biopharmaceuticals completes phase-II clinical trials in Respiratory syncytial virus infections (In volunteers, Prevention, In adults) in Australia (IM) (NCT04681833)
  • 04 Jun 2021 Adverse events data from a phase I trial in Respiratory syncytial virus infections released by Advaccine Biopharmaceuticals
  • 24 May 2021 Phase-II clinical trials in Respiratory syncytial virus infections (In volunteers, Prevention, In adults) in Australia (IM) (NCT04681833)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top